It is of note that clinical responses are heterogeneous, depending on the fusion subtype, according to recent scientific evidence in patients with ALK+ NSCLC [6], and this should impact the choice of ALKis in terms of adverse events and tolerability, which have gradually aroused attention [5]. This evidence concerns the gene ALK and non-small cell lung carcinoma.